BioPharmSignal logoBioPharmSignal

Biotech News

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio (MBIO)Mustang BioCompany update

MBIO (MBIO) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is mbio.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Mustang Bio

Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches. Its story is built around the possibility that targeted cell therapies can create differentiated outcomes in hard-to-treat cancers.

Recent company news

MBIOMustang Bio2025-07-07 12:30 EST

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

MBIOMustang Bio2025-03-05 21:15 EST

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

MBIOMustang Bio2025-02-27 21:05 EST

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

MBIOMustang Bio2025-02-11 21:10 EST

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

MBIOMustang Bio2025-02-10 13:00 EST

Mustang Bio Announces Closing of $8 Million Public Offering

Stock data

Close
0.58 USD
Market cap
5.77M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States